Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer.
Miller, Miles A
Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Feb 2017 - 623-629 p. digital
Publication Type: Journal Article; Review
1557-3265
10.1158/1078-0432.CCR-16-0869 doi
ADAM10 Protein--antagonists & inhibitors
ADAM17 Protein--antagonists & inhibitors
Antineoplastic Agents--metabolism
Body Fluids--chemistry
Drug Design
Drug Resistance, Neoplasm--physiology
Enzyme Activation
Humans
Immunotherapy
Macrophages--metabolism
Molecular Targeted Therapy
Neoplasm Proteins--analysis
Neoplasms--drug therapy
Peptide Fragments--analysis
Protein Domains
Protein Kinase Inhibitors--pharmacology
Proteolysis--drug effects
Receptors, Cell Surface--metabolism
Substrate Specificity
Tissue Inhibitor of Metalloproteinases--physiology
Tumor Microenvironment
Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Feb 2017 - 623-629 p. digital
Publication Type: Journal Article; Review
1557-3265
10.1158/1078-0432.CCR-16-0869 doi
ADAM10 Protein--antagonists & inhibitors
ADAM17 Protein--antagonists & inhibitors
Antineoplastic Agents--metabolism
Body Fluids--chemistry
Drug Design
Drug Resistance, Neoplasm--physiology
Enzyme Activation
Humans
Immunotherapy
Macrophages--metabolism
Molecular Targeted Therapy
Neoplasm Proteins--analysis
Neoplasms--drug therapy
Peptide Fragments--analysis
Protein Domains
Protein Kinase Inhibitors--pharmacology
Proteolysis--drug effects
Receptors, Cell Surface--metabolism
Substrate Specificity
Tissue Inhibitor of Metalloproteinases--physiology
Tumor Microenvironment